Danish pharmaceutical giant Novo Nordisk is gearing up to introduce its blockbuster anti-diabetes and weight-loss drug Wegovy (semaglutide) in India. In a strategic move to gain an advantage over Eli Lilly’s newly launched Mounjaro (tirzepatide), Novo Nordisk has presented data showcasing Wegovy’s cardiovascular benefits in Indian patients, according to recent regulatory filings.
Fuel Prices May Rise if Middle East Crisis Continues, Warns RBI Governor
Amid rising geopolitical tensions in the Middle East, the Reserve Bank of India (RBI) has indicated that prolonged instability in the region could lead to an increase in fuel prices in India....





Discussion about this post